TB-500
2.5–5 mg · 2×/week loading, then weekly
Evidence
- Human Studies
- 2
- Animal Studies
- 35
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Unknown — no controlled human safety data for the synthetic fragment specifically
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
A synthetic fragment of thymosin beta-4, studied in animal models for actin regulation involved in cell migration and wound healing. Naturally occurring thymosin beta-4 has more human research behind it than this synthetic fragment specifically.
Common Protocols
- 2.5–5 mg 2x/week for a loading phase, then weekly maintenance, subcutaneous
Side Effects
- Injection site irritation
- No systematic human safety data
Interactions
- No formal interaction data exists
Practical Details
- Cost
- $$
- Typical Vial Size
- 10 mg
- Storage
- Refrigerate after reconstitution
Research Links
Systemic tissue repair, flexibility